

2026

Network for Cardiovascular Pharmacogenomics and Precision Medicine



CA24165



Building a European Network for
Cardiovascular Pharmacogenomics and
Precision Medicine!

Content editors: SCC Theodora Katsila
and Deputy SCC Amra Džuho

Contact: info@cardiopharmagenet.eu

Duration: 29.10.2025. - 28.10.2029.

The first newsletter of the CardioPharmaGENET highlights the key milestones, collaborations and achievements of our network during its inaugural year.

As we continue to build a strong European community dedicated to advancing cardiovascular pharmacogenomics and precision medicine, this newsletter reflects the collective efforts of our members in research, training, networking, and scientific dissemination.



This newsletter is based upon work from COST Action CA24165 CardioPharmaGENET, supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.



About the CardioPharmaGENET

59 MC MEMBERS

FROM 37 COUNTRIES

301 ACTION PARTICIPANTS

FROM 42 COUNTRIES

4 YEARS

29/10/2025 – 28/10/2029

Data from 1st September, 2026.

CardioPharmaGENET is a pan-European scientific network dedicated to advancing cardiovascular pharmacogenomics and precision medicine.

By bringing together researchers, clinicians, geneticists, pharmacologists, bioinformaticians, policymakers, industry representatives, and patient stakeholders, the Action promotes interdisciplinary collaboration to accelerate the translation of pharmacogenomic evidence into routine cardiovascular care.

Through knowledge sharing, capacity building, and the development of evidence-based recommendations, CardioPharmaGENET aims to support safer, more effective, and more personalised cardiovascular therapies across Europe.

Aim of the Action

The primary aim of CardioPharmaGENET is to facilitate the implementation of pharmacogenomics in cardiovascular medicine by consolidating scientific evidence, strengthening collaboration across disciplines, and supporting the development of harmonised clinical and policy recommendations.

The Action seeks to bridge the gap between research and clinical practice, promote the responsible use of artificial intelligence and large-scale genomic data, enhance education and training opportunities, and foster a sustainable European network that advances personalised cardiovascular medicine while improving patient outcomes and reducing healthcare inequalities.



FIRST ANNUAL MEETING BRINGS THE CARDIOPHARMAGENET COMMUNITY TOGETHER

The first Annual Meeting of the Action was held from 11–13 May 2026 at GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt, Germany, bringing together researchers, clinicians, industry representatives, policymakers, patient stakeholders, and Young Researchers and Innovators from across Europe. The three-day programme included Management Committee and Core Group meetings, scientific sessions, Working Group discussions, and stakeholder engagement activities, covering pharmacogenomics in cardiovascular medicine, artificial intelligence, clinical translation, regulatory challenges, health economics, and science communication. Working Groups coordinated future deliverables and planned upcoming research, training, and dissemination activities. The meeting also highlighted the importance of cross-sector collaboration in advancing precision cardiovascular medicine and included a visit to the FAIR and GSI research facilities.



Follow CardioPharmaGENET and be part of the network shaping the future of personalised cardiovascular medicine.



[ABOUT](#) [ACTION STRUCTURE](#) [NEWS](#) [DELIVERABLES](#) [CONTACT](#) [Instagram](#) [LinkedIn](#)

Network for Cardiovascular Pharmacogenomics and Precision Medicine

CardioPharmaGENET aims to advance personalized medicine in cardiovascular care by leveraging pharmacogenomics (PGx) to optimize drug therapies. In cardiovascular medicine, this approach is especially critical, given the significant patient variability in drug responses to therapies.

Stay up to date with the latest news, opportunities, and activities within the CardioPharmaGENET COST Action by following our official website and social media channels. Through these platforms, you can receive timely updates on upcoming calls, networking opportunities, scientific events, and activities available for members of our growing community.

In the coming period, CardioPharmaGENET will announce new opportunities, including Short-Term Scientific Missions (STSMs), Dissemination Grants, Conference Grants, and Virtual Mobility Grants, providing valuable support for collaboration, knowledge exchange, and professional development. Looking ahead to the second year of the Action, we are also excited to launch our first CardioPharmaGENET Summer School, offering a dedicated opportunity for training, learning, and interdisciplinary exchange in the field of cardiovascular pharmacogenomics and precision medicine.

